• OPEN AN ACCOUNT
Indian Indices
Nifty
24,335.95 7.45
(0.03%)
Sensex
80,342.14 53.76
( 0.07%)
Bank Nifty
55,391.25 -41.55
( -0.07%)
Nifty IT
35,920.40 437.45
( 1.23%)
Global Indices
Nasdaq
40,538.66 290.07
(0.72%)
Dow Jones
5,579.50 29.75
(0.54%)
Hang Seng
36,006.39 166.40
(0.46%)
Nikkei 225
8,463.46 46.12
(0.55%)
Forex
USD-INR
85.20 -0.17
(-0.20%)
EUR-INR
96.93 -0.07
(-0.07%)
GBP-INR
113.83 0.22
(0.19%)
JPY-INR
0.60 0.00
(0.27%)

EQUITY - MARKET SCREENER

Zydus Life gains after USFDA approval for Niacin Extended-Release tablets
30-Apr-25   11:32 Hrs IST
The approved medication is indicated for the treatment of patients with primary hyperlipidemia and mixed dyslipidemia. It helps reduce elevated levels of total cholesterol (TC), LDL-C, apolipoprotein B (Apo B), and triglycerides (TG), while increasing HDL-C. It is also used to reduce the risk of recurrent myocardial infarction in patients with a prior history of heart attack and hyperlipidemia and to treat adults with severe hypertriglyceridemia.

According to IQVIA MAT (February 2025), the annual sales of Niacin Extended-Release tablets in the U.S. market were estimated at $5.5 million. With this latest approval, Zydus has now secured 425 product approvals and has filed a total of 492 Abbreviated New Drug Applications (ANDAs) since initiating the filing process in FY 2003'04.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter.

Powered by Capital Market - Live News